Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review

Abstract

Ying Li* Yanping Li* Junyu Li , Guoliang Pi, Wenyong Tan Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China *These authors contributed equally to this work Abstract: Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy. Keywords: cytotoxic drugs, PTX, CDDP, oncology, chemotherapy